AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00166257
Drug: Medical antitrhombotic treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
Trial: NCT01393509
Drug: PU-H71
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
Trial: NCT00006398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03681990
Drug: 3M CHG/IPA Prep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically to intact skin
Trial: NCT00174967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
Trial: NCT00408148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undistinguishable placebo tablets
Trial: NCT02666287
Drug: BAT/FF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
Trial: NCT01082588
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Trial: NCT01082588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Trial: NCT03490461
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
Trial: NCT02327338
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg ibuprofen administered 400mg at 4 hour intervals
Trial: NCT00318500
Drug: ERB-041
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01460498
Drug: Tyrosine kinase inhibitor (TKI)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of dose already receiving during previous 6 months.
Trial: NCT02429388
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
Trial: NCT03743103
Drug: Brevibloc, 10 Mg/mL Intravenous Solution
RxNorm normalized name: Brevibloc, 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/h every 5 minutes until reaching the pressure target
Trial: NCT02942381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03199482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administrated 30 minutes before start of root canal treatment
Trial: NCT00270361
Drug: usual long term cardiac medications
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04624958
Drug: R-DHAOx
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
Trial: NCT02255032
Drug: 0.8 mg CLS-TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
Trial: NCT02458339
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
Trial: NCT00402558
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
Trial: NCT03592537
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
Trial: NCT02989779
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01348308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks.
Trial: NCT03696108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
Trial: NCT02372799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02372799
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01456299
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.
Trial: NCT01456299
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml.
Trial: NCT01054300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ertugliflozin administered as a single dose
Trial: NCT04867993
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/kg/36h
Trial: NCT00707278
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
Trial: NCT02777970
Drug: Tramadol Hydrochloride/Dexketoprofen Trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02777970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03776604
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy.
Trial: NCT03663465
Drug: SGAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGAs tablet
Trial: NCT02008214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching pentoxifylline dosage
Trial: NCT00004474
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via IV over 60 minutes on Days -5 to -2
Trial: NCT02310425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: he control group (group C) did not receive S. boulardii (nor other probiotics)
Trial: NCT00087256
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02123953
Drug: TAK-438 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets
Trial: NCT03244540
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Trial: NCT00676312
Drug: PTH134
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00473070
Drug: Tobradex AF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04590534
Drug: Sildosin Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
Trial: NCT01062503
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
Trial: NCT02267772
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Acetaminophen
Trial: NCT03681574
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
Trial: NCT03681574
Drug: GABA 15mg/kg Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
Trial: NCT02091986
Drug: Symbicort pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
Trial: NCT02091986
Drug: Symbicort pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
Trial: NCT03681574
Drug: GABA 30mg/kg Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
Trial: NCT01744184
Drug: Entonox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entonox arm
Trial: NCT01033955
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
Trial: NCT01033955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical appearing encapsulated placebo.
Trial: NCT02701127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00462280
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04859582
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally BID on Days 1 to 14 Q3W
Trial: NCT03785067
Drug: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule taken orally once daily for 36 months
Trial: NCT03785067
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule taken orally once daily for 36 months
Trial: NCT03783936
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/m2
Trial: NCT03783936
Drug: 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
Trial: NCT00824980
Drug: IP10.C8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP10.C8 Gel 1%
Trial: NCT01208740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill three times daily
Trial: NCT00187330
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00474045
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target, dose titration, s.c. (under the skin) injection
Trial: NCT02839343
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
Trial: NCT02839343
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin IV, leucovorin IV and 5-FU IV
Trial: NCT01915576
Drug: BAY1125976
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
Trial: NCT01915576
Drug: BAY1125976
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
Trial: NCT01915576
Drug: BAY1125976
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
Trial: NCT00367965
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT00808639
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenously 30mg/m2 over 30 minutes
Trial: NCT00808639
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenously 30mg/ms over 15 minutes
Trial: NCT03053063
Drug: Placebo to match SEL 6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT03053063
Drug: Placebo to match SEL 18 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT00020943
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
Trial: NCT02890537
Drug: Core decompression/PREOB® implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Trial: NCT02890537
Drug: Core decompression/BMC implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
Trial: NCT00020943
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/sq m IVP Day 3, Tx 1\& 2
Trial: NCT00020943
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
Trial: NCT00020943
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
Trial: NCT00661661
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg BID up to 10 mg BID until launch
Trial: NCT03002064
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
Trial: NCT00489905
Drug: Zolderonic acid (Zometa)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01720498
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The effect site concentration of remifentanil
Trial: NCT03400176
Drug: VAY736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT03845582
Drug: ALK-001 oral capsule
RxNorm normalized name: ergot alkaloids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration for 24 months
Trial: NCT03845582
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration for 24 months
Trial: NCT02539576
Drug: ABC/DTG/3TC FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally.
Trial: NCT04989127
Drug: Antibiotics, Penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics are prescribed for the patients.
Trial: NCT01698918
Drug: Standard of care to treat stomatitis (Stomatitis sub-study)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
Trial: NCT02844699
Drug: Mobilan (M-VM3)
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
Trial: NCT02844699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% infusion solution of dextrose (glucose)
Trial: NCT00859651
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT02409563
Drug: Budesonide nasal spray (50 mcg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02151734
Drug: KALOMIN™ Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02151734
Drug: Umckamin syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299285
Drug: LY3009104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00965341
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
Trial: NCT00965341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
Trial: NCT04756154
Drug: CHG/IPA Surgical skin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically to the inguinal region for 2 minutes
Trial: NCT04756154
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically to the inguinal region for 2 minutes
Trial: NCT00129922
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00129922
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00251082
Drug: continuous combined estradiol and dydrogesterone
RxNorm normalized name: dydrogesterone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
Trial: NCT00251082
Drug: continuous combined estradiol and dydrogesterone
RxNorm normalized name: dydrogesterone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Mg Estradiol and 5 Mg Dydrogesterone
Trial: NCT00251082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00963027
Drug: Treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
Trial: NCT00454220
Drug: MRrhTSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33 patients to 0.01 mg MRrhTSH + 131-I arm
Trial: NCT00463827
Drug: matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01077739
Drug: fluorouracil (5FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard FOLFOX regimen